

**PRESS
RELEASE****STALLERGENES' GROWTH STRATEGY
RECOGNIZED AT THE BFM AWARDS**

Antony, France (November 17, 2009). Stallergenes picked up the “best stock market performance” prize at the BFM Awards ceremony held on November 16, 2009. This prize, organized by the French economics-oriented radio station BFM, is awarded to businesses for outstanding corporate performance during the course of the year.

In addition to recognizing its stock market performance, this prize is also testament to the winning strategy implemented by Stallergenes, which is now the seventh-ranked French pharmaceutical company.

A medium sized biopharmaceutical company (workforce of 850 – turnover of €171 million in 2008), Stallergenes focuses entirely on the development of immunotherapy (also known as desensitization therapy) products to prevent and treat allergy-related respiratory diseases.

A coherent corporate strategy

Stallergenes now boasts recognized expertise in its core business and has developed specific and innovative technologies and know-how to ensure that it has full control over the development and production process for its products.

The second world leader in its market, Stallergenes pioneered sublingual immunotherapy and, since 2003, has been committed to the development of a new therapeutic class: sublingual immunotherapy tablets. To this end, it is conducting an ambitious program, dubbed “Stalair[®]”, to develop 5 pharmaceutical products in tablet form designed to treat patients allergic to the commonest allergens: grass pollens (Oralair[®], already available in Germany), house dust mites (Actair[®]), birch, ragweed and Japanese cedar pollens. With these tablets, it will be possible to treat 80% of all patients suffering from severe respiratory allergies, not adequately controlled with symptomatic treatments.

Growth creating value

Since 2000, Stallergenes has been enjoying annual growth of 15%, leading to a fourfold increase in its business. As a result, it is now in a position to devote more than 20% of its turnover to R&D. Half of the company's profits are ploughed back into new facilities and new laboratories to pave the way for the future. The other half is shared equally between dividends paid out to shareholders and employee shareholding and profit-sharing schemes.

Stallergenes' growth in business has been accompanied by fundamental changes in the company itself, with the workforce more than doubling in the last 10 years. More than 400 new – and for the most part highly-qualified – jobs, for example, have been created at head office in Antony.

Stallergenes exports almost half of its products to nearly 50 countries, through 10 subsidiaries and a network of partners and distributors. The allergen tablets may be marketed in the USA and Japan, with one or more partners that the group plans to start seeking soon.

ABOUT STALLERGENES

Stallergenes is a European biopharmaceutical company dedicated to immunotherapy treatments for the prevention and treatment of allergy-related respiratory diseases, such as allergic rhinoconjunctivitis, rhinitis and asthma. A pioneer and leader in sublingual immunotherapy treatments, Stallergenes devotes 21% of its turnover, in gross terms, to Research and Development and is actively involved in the development of a new therapeutic class: sublingual immunotherapy tablets.

In 2008, Stallergenes had a turnover of 171 million euros and more than 500,000 patients were treated with Stallergenes immunotherapy products

Euronext Paris (Compartment B)
SBF 120.

ISIN code: FR0000065674
Reuters code: GEN.PA
Bloomberg code: GEN.FP

GENP
LISTED
NYSE
EURONEXT

Additional information is available at <http://www.stallergenes.com>



Contacts

Press relations

Lise Lemonnier – Communication Manager
Tel.: + 33 1 55 59 20 96
e-mail: llemonnier@stallergenes.fr

Investor and analyst relations

Lucile de Fraguier – Pavie Finance
Tel.: + 33 1 42 15 04 39
e-mail: contact@pavie-finance.com